ImmuniQ Overview
ImmuniQ has developed a method for quantifing the actual and functional tumor response to immunotherapy drugs. The company’s immune checkpoint artificial reporter (IcAR) technology is able to quantify binding and shows the actual surface activity of the patient’s cancer cells, enabling more effective treatment for each patient.
Latest News
No news articles.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Pre-Funding |
| Rounds | 0 |
| Investors | 0 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | www.immuniq.tech/ |
Photos & Videos
No files yet
ImmuniQ Business
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsCellsTags (4)
pharmaceuticalsdrug-discoveryimmunologycancerImmuniQ Financials
ImmuniQ Lifecycle
ImmuniQ News
0 articlesNo news articles.
ImmuniQ Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 3 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
ImmuniQ Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 82/100 |
| Missing | address, video or image, funding rounds, news, markets, external profiles, not claimed |
| BI Verification | Yanina Wainscheinker |
| Creator | Maor Perlov |
| Creator email | maor.perlov@sncentral.org |
| Last update | 2022-10-12T00:00:00.000Z |
| Created | 2022-10-12T00:00:00.000Z |